-+ 0.00%
-+ 0.00%
-+ 0.00%

Crinetics Pharmaceuticals Doses First Patient in Phase 3 Atumelnant Trial for Congenital Adrenal Hyperplasia

路透·12/11/2025 21:05:20

登錄查看新聞詳情